TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05821309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350
Description: The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-3350 with electrolytes
Description: The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerin
Description: Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerin
Description: Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
Study: NCT05629702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: Oromucosal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nabiximols-matched placebo
Description: Nabiximols-matched placebo oromucosal spray
Study: NCT05499637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor PET/CT
Description: \[68Ga\]Ga-PentixaFor PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor PET/CT
Description: \[68Ga\]Ga-PentixaFor PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor PET/CT
Description: \[68Ga\]Ga-PentixaFor PET/CT
Study: NCT06008691

Intervention type: DRUG
Intervention: novel MAB (alone or in combination)
Description: novel MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy
Study: NCT05823259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education
Description: A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy Care
Description: A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
Study: NCT06583031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose A1
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose A2
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose A3
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose B1
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose B2
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose B3
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose C1
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose C2
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose C3
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose 1
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose 2
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine dose 3
Description: Suspension for injection. Route of administration: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent RSV Vaccine
Description: Suspension for injection. Route of administration: IM injection
Study: NCT06353841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week in four weeks.
Study: NCT06433908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-152a
Description: 100 µg (ex-valve), given at 20-second intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-152a
Description: 100 µg (ex-valve), given at 20-second intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-134a
Description: 100 µg (ex-valve), given at 20-second intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-134a
Description: 100 µg (ex-valve), given at 20-second intervals.
Study: NCT06340906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: EA at 10 standardized acu-points that were chosen for their therapeutic effects: Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6), Shenmen (HT7), Hegu (LI4) bilateral, Zusanli (ST36), Sanyinjiao (SP6), Zhaohai (KI6), Taichong (LR3) bilateral, Tian Shu (ST25) bilateral.
Study: NCT06423703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR
Description: four times per day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
Study: NCT05597969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FoodCoach
Description: The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
Study: NCT04913753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CBEU
Description: Patients in the control group will have bacterial culture and double J removal will be performed as usual. .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No CBEU
Description: Patients in the experimental group will have bacterial culture and double J removal will be performed as usual. .
Study: NCT06302751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Care 4 Today ® (Johnson and Johnson) mobile app
Description: Care 4 Today ® (Johnson and Johnson) mobile app will cover the perioperative period spanning through the preoperative assessment day (approximately -seven to -one from surgery) to 30 days after surgery and will monitor the adherence to preoperative and postoperative recommendations.
Study: NCT05891002

Intervention type: DEVICE
Intervention: Cirq® Robotic Alignment Module Cranial
Description: Robotic navigation for cranial biopsy procedure
Study: NCT06213532

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation Intervention
Description: Multimedia program administered either remotely or in person

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Multimedia program administered either remotely or in person

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Multimedia program administered either remotely or in person

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Collection
Description: Saliva samples will be collected from each participant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Collection
Description: Saliva samples will be collected from each participant

Intervention type: OTHER
Group type: OTHER
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06462989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECHONEXT
Description: ECHONEXT Artificial intelligence algorithm
Study: NCT04747613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
Study: NCT05927350

Intervention type: OTHER
Intervention: Survey
Description: Survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
Study: NCT05287321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg with Aspirin 100mg
Study: NCT05339529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-
Description: Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Blank control
Description: Blank control
Study: NCT05935787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
Description: Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 15 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 25 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days
Study: NCT06385457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindhelper- A national youth mental health promotion website
Description: Mindhelper is an open-access, digital self-directed mental health service that provides information, self-help tools and guidance to young people in Denmark.
Study: NCT05842408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5212
Description: Test drug: DA-5212

Intervention type: DRUG
Group type: OTHER
Intervention: DA-5212-R
Description: Control drug: DA-5212-R
Study: NCT06213454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Anesthesia
Description: ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon-Initiated Local Anesthetic
Description: 266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
Study: NCT05195645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept 250 MG
Description: Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept 250 MG
Description: Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept 250 MG
Description: Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
Study: NCT04118530

Intervention type: OTHER
Intervention: HSCT Patients
Description: Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
Study: NCT06501781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Activate-LAI
Description: Peer Activate-LAI is a Peer Recovery Specialist-delivered behavioral activation and problem solving intervention, based on our team's formative work. The intervention focuses on problem-solving skills to improve adherence to ART and/or PrEP both at the individual level and environmental barriers to care (i.e., transportation, housing).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care HIV treatment or prevention with LAI-PrEP/ART
Description: Standard of care HIV treatment or prevention with LAI-PrEP/ART

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care HIV treatment or prevention with LAI-PrEP/ART
Description: Standard of care HIV treatment or prevention with LAI-PrEP/ART
Study: NCT05671848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recordings of thalamic activity
Description: Recordings of thalamic activity will be performed at home, in ecological conditions. They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements. For these recordings, stimulation will be either turned Off or On. Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
Study: NCT06348238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Affirmation
Description: Self-affirmation theory contends that integrity of one's self-concept (self integrity) is essential for navigating daily stressors. When individuals encounter information or contexts that pose a threat to one's self-integrity, we can adopt maladaptive coping strategies to alleviate the discomfort. One strategy for strengthening self-integrity is engage in an explicit process of reinforcing sources of self-worth - self-affirmation. Self affirmation interventions have participants engage in an exercise writing about core personal values (a writing induction). In a writing induction, participants review a list of values and are instructed to choose up to two that are important to them. Participants are then asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self-Affirmation
Description: Self-affirmation theory contends that integrity of one's self-concept (self integrity) is essential for navigating daily stressors. When individuals encounter information or contexts that pose a threat to one's self-integrity, we can adopt maladaptive coping strategies to alleviate the discomfort. One strategy for strengthening self-integrity is engage in an explicit process of reinforcing sources of self-worth - self-affirmation. Self affirmation interventions have participants engage in an exercise writing about core personal values (a writing induction). In a writing induction, participants review a list of values and are instructed to choose up to two that are important to them. Participants are then asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges.
Study: NCT06315075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for adolescents (DBT-A)
Description: A 20-week DBT-A with a weekly individual session (45 minutes), a weekly session of multifamily skills training groups with a caregiver (120 minutes), and telephone consultation with individual therapists outside therapy sessions as needed. The treatment consists of four components and is delivered according to the manual except for the phone coaching that PBU offers workdays until 8 pm.
Study: NCT06283472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Cue
Description: Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Cue
Description: Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
Study: NCT05305664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen (TQJ230) 80 mg s.c.
Description: Pelacarsen (TQJ230) 80 mg s.c. Q4W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corresponding Placebo
Description: Placebo to Pelacarsen
Study: NCT06386315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Procedure
Description: Undergo endoscopy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-site Radiation Therapy (3 Fractions)
Description: Undergo ISRT in 3 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved-site Radiation Therapy (12 Fractions)
Description: Undergo ISRT in 12 fractions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies